Novartis’ ofatumumab data comparable to Ocrevus in RRMS

Roche’s blockbuster MS therapy Ocrevus ocrelizumab could soon have company in relapsing-remitting multiple sclerosis as Phase III data presented Friday for ofatumumab by Novartis show the two anti-CD20 mAbs could have comparable efficacy.

Data from the

Read the full 356 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE